Immune Pharmaceuticals Inc. - Product Pipeline Review - 2016 - Global Markets Direct - Market Research

Immune Pharmaceuticals Inc. - Product Pipeline Review - 2016

Immune Pharmaceuticals Inc. - Product Pipeline Review - 2016 - Global Markets Direct - Market Research
Immune Pharmaceuticals Inc. - Product Pipeline Review - 2016
Published Jul 27, 2016
61 pages — Published Jul 27, 2016
Price US$ 1,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Immune Pharmaceuticals Inc. - Product Pipeline Review, 2016, provides an overview of the Immune Pharmaceuticals Inc.s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immune Pharmaceuticals Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Immune Pharmaceuticals Inc.
- The report provides overview of Immune Pharmaceuticals Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Immune Pharmaceuticals Inc.s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Immune Pharmaceuticals Inc.s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Immune Pharmaceuticals Inc.s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Immune Pharmaceuticals Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Immune Pharmaceuticals Inc.s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  
Source:
Document ID
GMDHC08099CDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Immune Pharmaceuticals Inc. Snapshot61
  Immune Pharmaceuticals Inc. Overview61
  Key Information61
  Key Facts61
Immune Pharmaceuticals Inc. Research and Development Overview73
  Key Therapeutic Areas73
Immune Pharmaceuticals Inc. Pipeline Review105
  Pipeline Products by Stage of Development101
  Pipeline Products Monotherapy111
  Pipeline Products Combination Treatment Modalities121
  Pipeline Products Partnered Products131
    Partnered Products/Combination Treatment Modalities141
Immune Pharmaceuticals Inc. Pipeline Products Glance155
  Immune Pharmaceuticals Inc. Late Stage Pipeline Products151
    Phase III Products/Combination Treatment Modalities151
  Immune Pharmaceuticals Inc. Clinical Stage Pipeline Products161
    Phase II Products/Combination Treatment Modalities161
    Phase I Products/Combination Treatment Modalities171
  Immune Pharmaceuticals Inc. Early Stage Pipeline Products181
    IND/CTA Filed Products/Combination Treatment Modalities181
    Preclinical Products/Combination Treatment Modalities191
Immune Pharmaceuticals Inc. Drug Profiles2022
  histamine dihydrochloride201
    Product Description201
    Mechanism of Action201
    R&D Progress203
  (amitriptyline + ketamine hydrochloride)231
    Product Description231
    Mechanism of Action231
    R&D Progress232
  bertilimumab251
    Product Description251
    Mechanism of Action251
    R&D Progress252
  crolibulin271
    Product Description271
    Mechanism of Action271
    R&D Progress272
  lidocaine hydrochloride291
    Product Description291
    Mechanism of Action291
    R&D Progress292
  F-573311
    Product Description311
    Mechanism of Action311
    R&D Progress311
  cyclosporine321
    Product Description321
    Mechanism of Action321
    R&D Progress321
  Ferritizumab331
    Product Description331
    Mechanism of Action331
    R&D Progress331
  Monoclonal Antibodies to Target HLA-DR and CD5 for Leukemia341
    Product Description341
    Mechanism of Action341
    R&D Progress341
  Monoclonal Antibody Conjugate for Non-Small Cell Lung Cancer and Pancreatic Cancer351
    Product Description351
    Mechanism of Action351
    R&D Progress351
  Monoclonal Antibody Conjugate to Target EGFR for Non-Small Cell Lung Cancer361
    Product Description361
    Mechanism of Action361
    R&D Progress361
  Monoclonal Antibody Conjugate to Target HER2 for Metastatic Prostate Cancer371
    Product Description371
    Mechanism of Action371
    R&D Progress371
  Monoclonal Antibody Conjugate to Target HER3 for Solid Tumors381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  verubulin391
    Product Description391
    Mechanism of Action391
    R&D Progress393
Immune Pharmaceuticals Inc. Pipeline Analysis426
  Immune Pharmaceuticals Inc. Pipeline Products by Target422
  Immune Pharmaceuticals Inc. Pipeline Products by Route of Administration441
  Immune Pharmaceuticals Inc. Pipeline Products by Molecule Type451
  Immune Pharmaceuticals Inc. Pipeline Products by Mechanism of Action462
Immune Pharmaceuticals Inc. Recent Pipeline Updates489
Immune Pharmaceuticals Inc. Dormant Projects571
Immune Pharmaceuticals Inc. Discontinued Pipeline Products581
  Discontinued Pipeline Product Profiles581
    histamine dihydrochloride581
    verubulin581
Immune Pharmaceuticals Inc. Locations And Subsidiaries591
  Head Office591
  Other Locations &Subsidiaries591
Appendix602
  Methodology601
  Coverage601
  Secondary Research601
  Primary Research601
  Expert Panel Validation601
  Contact Us601
  Disclaimer611

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Immune Pharmaceuticals Inc. - Product Pipeline Review - 2016" Jul 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Immune-Pharmaceuticals-Inc-Product-Pipeline-Review-2016-2088-16207>
  
APA:
Global Markets Direct - Market Research. (2016). Immune Pharmaceuticals Inc. - Product Pipeline Review - 2016 Jul 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Immune-Pharmaceuticals-Inc-Product-Pipeline-Review-2016-2088-16207>
  
US$ 1,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.